-

06:47:14 PM

LIVE Real Time EBS Stock Market News

EBS - Emergent Biosolutions Inc

04/21/21 12:46 PM

NYSE : EBS

Statement on Issuance of Form FDA 483 at Emergent Bayview Facility

The U.S. Food and Drug Administration (FDA) has completed its inspection of Emergent BioSolutions' (NYSE:EBS) Baltimore-Bayview facility and provided specific feedback. Given the heightened focus on this facility, the FDA has proactively

RHEA-AI

very positive

04/15/21 6:30 AM

NYSE : EBS

Emergent BioSolutions to Release First Quarter 2021 Financial Results and Conduct a Conference Call on April 29, 2021

Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Thursday, April 29, 2021 at 5:00 pm eastern time to discuss the financial results for the first quarter of 2021, recent business developments, revenue guidance for the

RHEA-AI

neutral

04/08/21 11:51 AM

NYSE : EBS

Entwistle & Cappucci LLP Investigative Alert: Emergent BioSolutions Inc. (EBS)

Entwistle & Cappucci LLP ("Entwistle & Cappucci") is investigating potential federal securities law violations on behalf of clients that invested in Emergent BioSolutions Inc. ("Emergent" or the "Company") (NYSE: EBS) based on: (i) the Company's contamination of at least 15 million doses of the

RHEA-AI

negative

04/04/21 10:09 PM

NYSE : EBS

Emergent BioSolutions On Track with Respect to COVID-19 Contractual Commitments; Receives Modified Task Order from the U.S. Department of Health & Human Services to Support the Opportunity for Further Expansion of Manufacturing Capacity for Johnson & Johnson's COVID-19 Vaccine

Emergent BioSolutions Inc. (NYSE:EBS) today announced that the Company continues to be on track

RHEA-AI

very positive

04/02/21 8:00 AM

NYSE : EBS

Emergent BioSolutions Announces Topline Data from NIAID Phase 3 ITAC Trial (INSIGHT-013) Evaluating Immunoglobulins as a Treatment for Hospitalized Patients with COVID-19

Emergent BioSolutions Inc. (NYSE:EBS) today provided an update on the evaluation of its investigational SARS-CoV-2 Immune Globulin Intravenous (Human) (COVID-HIG) for the treatment of hospitalized patients with COVID-19. The Phase 3 Inpatient

RHEA-AI

neutral

03/01/21 6:30 AM

NYSE : EBS

Emergent BioSolutions to Participate in Investor Conferences

Emergent BioSolutions Inc. (NYSE: EBS) announced today that members of the company's senior management team will participate in the following investor conferences: Jefferies Inaugural Global Plasma Summit March 11, 2021 Company fireside chat

RHEA-AI

neutral

02/18/21 4:05 PM

NYSE : EBS

Emergent BioSolutions Reports Financial Results for Fourth Quarter and Full Year 2020

Emergent BioSolutions Inc. (NYSE: EBS) today reported financial results for the quarter and year ended December 31,

RHEA-AI

positive

02/04/21 6:30 AM

NYSE : EBS

Emergent BioSolutions to Release Fourth Quarter and Full Year 2020 Financial Results and Conduct a Conference Call on February 18, 2021

Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Thursday, February 18, 2021 at 5:00 pm eastern time to discuss the financial results for the fourth quarter and full year 2020, recent business developments, financial

RHEA-AI

neutral

01/25/21 8:30 AM

Nasdaq, NYSE : HGEN, EBS

Humanigen and Emergent BioSolutions Announce Contract Development and Manufacturing Agreement for Phase 3 COVID-19 Therapeutic Candidate Lenzilumab(TM)

Emergent BioSolutions Inc. (NYSE:EBS) (Emergent) and Humanigen, Inc. (NASDAQ:HGEN) (Humanigen) today announced that they have entered into a contract development and manufacturing (CDMO) services agreement to accelerate the drug product manufacturing of lenzilumab(TM), an anti-human granulocyte

RHEA-AI

very positive

01/04/21 6:30 AM

NYSE : EBS

Emergent BioSolutions to Participate in Investor Conferences

Emergent BioSolutions Inc. (NYSE: EBS) announced today that members of the company's executive management team will participate in the following investor conferences in the first quarter of 2021: 39th Annual J.P. Morgan Healthcare Conference

RHEA-AI

neutral